The role of cell-penetrating peptide and transferrin on enhanced delivery of drug to brain

International Journal of Molecular Sciences

Volumn 17, Issue 6, 2016, Pages

  Sharma, Gitanjali ^a   Lakkadwala, Sushant ^a   Modgil, Amit ^b   Singh, Jagdish ^a  

^a NORTH DAKOTA STATE UNIVERSITY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blood brain barrier (BBB); Cell penetrating peptide (CPPs); Functionalization; Liposomes; Transferrin

Indexed keywords

ARGININE; DOXORUBICIN; LIPOFECTIN; LIPOPROTEIN RECEPTOR; LIPOSOME; MASTOPARAN; MULTIDRUG RESISTANCE PROTEIN; NANOCARRIER; NANOPARTICLE; PENETRATIN; PEPTIDE; SERUM ALBUMIN; TRANSFERRIN; CELL PENETRATING PEPTIDE; TRANSFERRIN RECEPTOR;

BIOCOMPATIBILITY; BLOOD BRAIN BARRIER; BRAIN HEMORRHAGE; BRAIN INJURY; CENTRAL NERVOUS SYSTEM DISEASE; GENE DELIVERY SYSTEM; GENE EXPRESSION; HUMAN; LIPID COMPOSITION; MACROPHAGE; NANOTECHNOLOGY; PERMEABILITY; POLARIZATION; RECEPTOR UPREGULATION; REVIEW; TRANSCYTOSIS; CELL MEMBRANE PERMEABILITY; CHEMISTRY; DRUG DELIVERY SYSTEM; METABOLISM; PROCEDURES;

BLOOD-BRAIN BARRIER; CELL MEMBRANE PERMEABILITY; CELL-PENETRATING PEPTIDES; DRUG DELIVERY SYSTEMS; RECEPTORS, TRANSFERRIN; TRANSFERRIN;

EID: 85015591941     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17060806     Document Type: Review

References (149)

1. Bradbury, M. The Concept of a Blood–Brain Barrier; John Wiley and Sons Ltd.: New York, NY, USA, 1979.
2. Roth, L.J.; Barlow, C.F. Drugs in the brain: Autoradiography and radioassay techniques permit analysis of penetration by labeled drugs. Science 1961, 134, 22–31. [CrossRef] [PubMed]
3. Banks, W.A. Drug delivery to the brain in Alzheimer’s disease: Consideration of the blood-brain barrier. Adv. Drug Deliv. Rev. 2012, 64, 629–639. [CrossRef] [PubMed]
4. Davson, H.; Segal, M.B. Blood–Brain Barrier, Physiology of the csf and Blood–Brain Barriers; CRC Press: Boca Raton, FL, USA, 1996; pp. 49–91.
5. Cserr, H.F.; Knopf, P.M. Cervical lymphatics, the blood–brain barrier and the immunoreactivity of the brain: A new view. Immunol. Today 1992, 13, 507–512. [CrossRef]
6. Knopf, P.M.; Cserr, H.F.; Nolan, S.C.; Wu, T.Y.; Harling-Berg, C.J. Physiology and immunology of lymphatic drainage of interstitial and cerebrospinal fluid from the brain. Neuropathol. Appl. Neurobiol. 1995, 21, 175–180. [CrossRef] [PubMed]
7. Chen, Y.; Liu, L. Modern methods for delivery of drugs across the blood–brain barrier. Adv. Drug Deliv. Rev. 2012, 64, 640–665. [CrossRef] [PubMed]
8. Johanson, C.E.; Duncan, J.A., 3rd; Klinge, P.M.; Brinker, T.; Stopa, E.G.; Silverberg, G.D. Multiplicity of cerebrospinal fluid functions: New challenges in health and disease. Cerebrospinal Fluid Res. 2008, 5, 441–450. [CrossRef] [PubMed]
9. Townsend, S.A.; Evrony, G.D.; Gu, F.X.; Schulz, M.P.; Brown, R.H., Jr.; Langer, R. Tetanus toxin c fragment-conjugated nanoparticles for targeted drug delivery to neurons. Biomaterials 2007, 28, 5176–5184. [CrossRef] [PubMed]
10. Rip, J.; Schenk, G.J.; de Boer, A.G. Differential receptor-mediated drug targeting to the diseased brain. Expert Opin. Drug Deliv. 2009, 6, 227–237. [CrossRef] [PubMed]
11. Pathan, S.A.; Iqbal, Z.; Zaidi, S.M.; Talegaonkar, S.; Vohra, D.; Jain, G.K.; Azeem, A.; Jain, N.; Lalani, J.R.; Khar, R.K.; et al. CNS drug delivery systems: Novel approaches. Recent Pat. Drug Deliv. Formul. 2009, 3, 71–89. [CrossRef] [PubMed]
12. Pardridge, W.M. Blood–brain barrier drug targeting: The future of brain drug development. Mol. Interv. 2003, 3, 90–105, 151. [CrossRef] [PubMed]
13. Hawkins, B.T.; Egleton, R.D. Pathophysiology of the blood–brain barrier: Animal models and methods. Curr. Top. Dev. Biol. 2008, 80, 277–309. [PubMed]
14. Rousselle, C.; Clair, P.; Lefauconnier, J.M.; Kaczorek, M.; Scherrmann, J.M.; Temsamani, J. New advances in the transport of doxorubicin through the blood–brain barrier by a peptide vector-mediated strategy. Mol. Pharmacol. 2000, 57, 679–686. [PubMed]
15. Drin, G.; Cottin, S.; Blanc, E.; Rees, A.R.; Temsamani, J. Studies on the internalization mechanism of cationic cell-penetrating peptides. J. Biol. Chem. 2003, 278, 31192–31201. [CrossRef] [PubMed]
16. Sharma, G.; Modgil, A.; Sun, C.; Singh, J. Grafting of cell-penetrating peptide to receptor-targeted liposomes improves their transfection efficiency and transport across blood–brain barrier model. J. Pharm. Sci. 2012, 101, 2468–2478. [CrossRef] [PubMed]
17. Sharma, G.; Modgil, A.; Layek, B.; Arora, K.; Sun, C.; Law, B.; Singh, J. Cell penetrating peptide tethered bi-ligand liposomes for delivery to brain in vivo: Biodistribution and transfection. J. Control. Release 2013, 167, 1–10. [CrossRef] [PubMed]
18. Sharma, G.; Modgil, A.; Zhong, T.; Sun, C.; Singh, J. Influence of short-chain cell-penetrating peptides on transport of doxorubicin encapsulating receptor-targeted liposomes across brain endothelial barrier. Pharm. Res. 2014, 31, 1194–1209. [CrossRef] [PubMed]
19. Serwer, L.P.; James, C.D. Challenges in drug delivery to tumors of the central nervous system: An overview of pharmacological and surgical considerations. Adv. Drug Deliv. Rev. 2012, 64, 590–597. [CrossRef] [PubMed]
20. Scherrmann, J.M. Drug delivery to brain via the blood–brain barrier. Vasc. Pharmacol. 2002, 38, 349–354. [CrossRef]
21. Kohane, D.S.; Plesnila, N.; Thomas, S.S.; Le, D.; Langer, R.; Moskowitz, M.A. Lipid-sugar particles for intracranial drug delivery: Safety and biocompatibility. Brain Res. 2002, 946, 206–213. [CrossRef]
22. Qin, Y.; Chen, H.; Yuan, W.; Kuai, R.; Zhang, Q.; Xie, F.; Zhang, L.; Zhang, Z.; Liu, J.; He, Q. Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery. Int. J. Pharm. 2011, 419, 85–95. [CrossRef] [PubMed]
23. Stewart, P. Endothelial vesicles in the blood–brain barrier: Are they related to permeability? Cell. Mol. Neurobiol. 2000, 20, 149–163. [CrossRef] [PubMed]
24. Abbott, N.J. Dynamics of CNS barriers: Evolution, differentiation, and modulation. Cell. Mol. Neurobiol. 2005, 25, 5–23. [CrossRef] [PubMed]
25. Oldendorf, W.H.; Cornford, M.E.; Brown, W.J. The large apparent work capability of the blood-brain barrier: A study of the mitochondrial content of capillary endothelial cells in brain and other tissues of the rat. Ann. Neurol. 1977, 1, 409–417. [CrossRef] [PubMed]
26. Abbott, N.J.; Ronnback, L.; Hansson, E. Astrocyte-endothelial interactions at the blood–brain barrier. Nat. Rev. Neurosci. 2006, 7, 41–53. [CrossRef] [PubMed]
27. Ramsauer, M.; Kunz, J.; Krause, D.; Dermietzel, R. Regulation of a blood-brain barrier-specific enzyme expressed by cerebral pericytes (pericytic aminopeptidase N/pAPN) under cell culture conditions. J. Cereb. Blood Flow Metab. 1998, 18, 1270–1281. [CrossRef] [PubMed]
28. Ramsauer, M.; Krause, D.; Dermietzel, R. Angiogenesis of the blood–brain barrier in vitro and the function of cerebral pericytes. FASEB J. 2002, 16, 1274–1276. [CrossRef] [PubMed]
29. Dohgu, S.; Takata, F.; Yamauchi, A.; Nakagawa, S.; Egawa, T.; Naito, M.; Tsuruo, T.; Sawada, Y.; Niwa, M.; Kataoka, Y. Brain pericytes contribute to the induction and up-regulation of blood-brain barrier functions through transforming growth factor-β production. Brain Res. 2005, 1038, 208–215. [CrossRef] [PubMed]
30. Wekerle, H. Immune protection of the brain—Efficient and delicate. J. Infect. Dis. 2002, 186, S140–S144. [CrossRef] [PubMed]
31. Daneman, R.; Rescigno, M. The gut immune barrier and the blood–brain barrier: Are they so different? Immunity 2009, 31, 722–735. [CrossRef] [PubMed]
32. Williams, K.; Alvarez, X.; Lackner, A.A. Central nervous system perivascular cells are immunoregulatory cells that connect the CNS with the peripheral immune system. Glia 2001, 36, 156–164. [CrossRef] [PubMed]
33. Streit, W.J.; Conde, J.R.; Fendrick, S.E.; Flanary, B.E.; Mariani, C.L. Role of microglia in the central nervous system’s immune response. Neurol. Res. 2005, 27, 685–691. [PubMed]
34. Levin, V.A. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem. 1980, 23, 682–684. [CrossRef] [PubMed]
35. Pardridge, W.; Kang, Y.-S.; Buciak, J.; Yang, J. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood–brain barrier in vivo in the primate. Pharm. Res. 1995, 12, 807–816. [CrossRef] [PubMed]
36. Terasaki, T.; Ohtsuki, S.; Hori, S.; Takanaga, H.; Nakashima, E.; Hosoya, K. New approaches to in vitro models of blood-brain barrier drug transport. Drug Discov. Today 2003, 8, 944–954. [CrossRef]
37. Roney, C.; Kulkarni, P.; Arora, V.; Antich, P.; Bonte, F.; Wu, A.; Mallikarjuana, N.N.; Manohar, S.; Liang, H.F.; Kulkarni, A.R.; et al. Targeted nanoparticles for drug delivery through the blood–brain barrier for Alzheimer’s disease. J. Control. Release 2005, 108, 193–214. [CrossRef] [PubMed]
38. Foust, K.D.; Nurre, E.; Montgomery, C.L.; Hernandez, A.; Chan, C.M.; Kaspar, B.K. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 2009, 27, 59–65. [CrossRef] [PubMed]
39. Abbott, N.J. Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol. Neurobiol. 2000, 20, 131–147. [CrossRef] [PubMed]
40. Lopez-Ramirez, M.A.; Wu, D.; Pryce, G.; Simpson, J.E.; Reijerkerk, A.; King-Robson, J.; Kay, O.; de Vries, H.E.; Hirst, M.C.; Sharrack, B.; et al. MicroRNA-155 negatively affects blood–brain barrier function during neuroinflammation. FASEB J. 2014, 28, 2551–2565. [CrossRef] [PubMed]
41. Schmidt, N.; Mishra, A.; Lai, G.H.; Wong, G.C. Arginine-rich cell-penetrating peptides. FEBS Lett. 2010, 584, 1806–1813. [CrossRef] [PubMed]
42. Snyder, E.L.; Dowdy, S.F. Cell penetrating peptides in drug delivery. Pharm. Res. 2004, 21, 389–393. [CrossRef] [PubMed]
43. Lewin, M.; Carlesso, N.; Tung, C.H.; Tang, X.W.; Cory, D.; Scadden, D.T.; Weissleder, R. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat. Biotechnol. 2000, 18, 410–414. [PubMed]
44. Torchilin, V.P.; Rammohan, R.; Weissig, V.; Levchenko, T.S. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc. Natl. Acad. Sci. USA 2001, 98, 8786–8791. [CrossRef] [PubMed]
45. Torchilin, V.P.; Levchenko, T.S.; Rammohan, R.; Volodina, N.; Papahadjopoulos-Sternberg, B.; D’Souza, G.G. Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc. Natl. Acad. Sci. USA 2003, 100, 1972–1977. [CrossRef] [PubMed]
46. Huwyler, J.; Wu, D.; Pardridge, W.M. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. USA 1996, 93, 14164–14169. [CrossRef] [PubMed]
47. Yamano, S.; Dai, J.; Hanatani, S.; Haku, K.; Yamanaka, T.; Ishioka, M.; Takayama, T.; Yuvienco, C.; Khapli, S.; Moursi, A.M.; et al. Long-term efficient gene delivery using polyethylenimine with modified TAT peptide. Biomaterials 2014, 35, 1705–1715. [CrossRef] [PubMed]
48. Trabulo, S.; Cardoso, A.L.; Mano, M.; de Lima, M.C.P. Cell-penetrating peptides—Mechanisms of cellular uptake and generation of delivery systems. Pharmaceuticals 2010, 3, 961. [CrossRef]
49. Li, J.; Zhang, X.; Wang, M.; Li, X.; Mu, H.; Wang, A.; Liu, W.; Li, Y.; Wu, Z.; Sun, K. Synthesis of a bi-functional dendrimer-based nanovehicle co-modified with RGDyC and TAT peptides for neovascular targeting and penetration. Int. J. Pharm. 2016, 501, 112–123. [CrossRef] [PubMed]
50. Kibria, G.; Hatakeyama, H.; Ohga, N.; Hida, K.; Harashima, H. Dual-ligand modification of pegylated liposomes shows better cell selectivity and efficient gene delivery. J. Control. Release 2011, 153, 141–148. [CrossRef] [PubMed]
51. Cheng, J.; Teply, B.A.; Sherifi, I.; Sung, J.; Luther, G.; Gu, F.X.; Levy-Nissenbaum, E.; Radovic-Moreno, A.F.; Langer, R.; Farokhzad, O.C. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 2007, 28, 869–876. [CrossRef] [PubMed]
52. Zheng, C.; Ma, C.; Bai, E.; Yang, K.; Xu, R. Transferrin and cell-penetrating peptide dual-functioned liposome for targeted drug delivery to glioma. Int. J. Clin. Exp. Med. 2015, 8, 1658–1668. [PubMed]
53. Opanasopit, P.; Tragulpakseerojn, J.; Apirakaramwong, A.; Ngawhirunpat, T.; Rojanarata, T.; Ruktanonchai, U. The development of poly-L-arginine-coated liposomes for gene delivery. Int. J. Nanomed. 2011, 6, 2245–2252. [CrossRef] [PubMed]
54. Disalvo, E.A.; Bouchet, A.M. Electrophoretic mobility and ζ potential of liposomes due to arginine and polyarginine adsorption. Colloids Surf. A 2014, 440, 170–174. [CrossRef]
55. Zhang, C.; Tang, N.; Liu, X.; Liang, W.; Xu, W.; Torchilin, V.P. SiRNA-containing liposomes modified with polyarginine effectively silence the targeted gene. J. Control. Release 2006, 112, 229–239. [CrossRef] [PubMed]
56. Mäe, M.; Myrberg, H.; El-Andaloussi, S.; Langel, Ü. Design of a tumor homing cell-penetrating peptide for drug delivery. Int. J. Pept. Res. Ther. 2009, 15, 11–15. [CrossRef]
57. Ziegler, A.; Nervi, P.; Durrenberger, M.; Seelig, J. The cationic cell-penetrating peptide CPP(TAT) derived from the HIV-1 protein TAT is rapidly transported into living fibroblasts: Optical, biophysical, and metabolic evidence. Biochemistry 2005, 44, 138–148. [CrossRef] [PubMed]
58. Rudolph, C.; Schillinger, U.; Ortiz, A.; Tabatt, K.; Plank, C.; Muller, R.H.; Rosenecker, J. Application of novel solid lipid nanoparticle (SLN)-gene vector formulations based on a dimeric HIV-1 TAT-peptide in vitro and in vivo. Pharm. Res. 2004, 21, 1662–1669. [CrossRef] [PubMed]
59. Suk, J.S.; Suh, J.; Choy, K.; Lai, S.K.; Fu, J.; Hanes, J. Gene delivery to differentiated neurotypic cells with RGD and HIV TAT peptide functionalized polymeric nanoparticles. Biomaterials 2006, 27, 5143–5150. [CrossRef] [PubMed]
60. Gupta, B.; Levchenko, T.S.; Torchilin, V.P. TAT peptide-modified liposomes provide enhanced gene delivery to intracranial human brain tumor xenografts in nude mice. Oncol. Res. 2007, 16, 351–359. [PubMed]
61. Barany-Wallje, E.; Keller, S.; Serowy, S.; Geibel, S.; Pohl, P.; Bienert, M.; Dathe, M. A critical reassessment of penetratin translocation across lipid membranes. Biophys. J. 2005, 89, 2513–2521. [CrossRef] [PubMed]
62. Drin, G.; Mazel, M.; Clair, P.; Mathieu, D.; Kaczorek, M.; Temsamani, J. Physico-chemical requirements for cellular uptake of pantp peptide. Role of lipid-binding affinity. Eur. J. Biochem. 2001, 268, 1304–1314. [CrossRef] [PubMed]
63. Scheller, A.; Wiesner, B.; Melzig, M.; Bienert, M.; Oehlke, J. Evidence for an amphipathicity independent cellular uptake of amphipathic cell-penetrating peptides. Eur. J. Biochem. 2000, 267, 6043–6050. [CrossRef] [PubMed]
64. Dom, G.; Shaw-Jackson, C.; Matis, C.; Bouffioux, O.; Picard, J.J.; Prochiantz, A.; Mingeot-Leclercq, M.P.; Brasseur, R.; Rezsohazy, R. Cellular uptake of antennapedia penetratin peptides is a two-step process in which phase transfer precedes a tryptophan-dependent translocation. Nucleic Acids Res. 2003, 31, 556–561. [CrossRef] [PubMed]
65. Xia, H.; Gao, X.; Gu, G.; Liu, Z.; Hu, Q.; Tu, Y.; Song, Q.; Yao, L.; Pang, Z.; Jiang, X.; et al. Penetratin-functionalized PEG-PLA nanoparticles for brain drug delivery. Int. J. Pharm. 2012, 436, 840–850. [CrossRef] [PubMed]
66. Christiaens, B.; Dubruel, P.; Grooten, J.; Goethals, M.; Vandekerckhove, J.; Schacht, E.; Rosseneu, M. Enhancement of polymethacrylate-mediated gene delivery by penetratin. Eur. J. Pharm. Sci. 2005, 24, 525–537. [CrossRef] [PubMed]
67. Massodi, I.; Bidwell, G.L., 3rd; Raucher, D. Evaluation of cell penetrating peptides fused to elastin-like polypeptide for drug delivery. J. Control. Release 2005, 108, 396–408. [CrossRef] [PubMed]
68. Yandek, L.E.; Pokorny, A.; Floren, A.; Knoelke, K.; Langel, U.; Almeida, P.F. Mechanism of the cell-penetrating peptide transportan 10 permeation of lipid bilayers. Biophys. J. 2007, 92, 2434–2444. [CrossRef] [PubMed]
69. Hallbrink, M.; Floren, A.; Elmquist, A.; Pooga, M.; Bartfai, T.; Langel, U. Cargo delivery kinetics of cell-penetrating peptides. Biochim. Biophys. Acta 2001, 1515, 101–109. [CrossRef]
70. Pooga, M.; Kut, C.; Kihlmark, M.; Hallbrink, M.; Fernaeus, S.; Raid, R.; Land, T.; Hallberg, E.; Bartfai, T.; Langel, U. Cellular translocation of proteins by transportan. FASEB J. 2001, 15, 1451–1453. [CrossRef] [PubMed]
71. Deshayes, S.; Morris, M.C.; Divita, G.; Heitz, F. Cell-penetrating peptides: Tools for intracellular delivery of therapeutics. Cell Mol. Life Sci. 2005, 62, 1839–1849. [CrossRef] [PubMed]
72. Saar, K.; Lindgren, M.; Hansen, M.; Eiriksdottir, E.; Jiang, Y.; Rosenthal-Aizman, K.; Sassian, M.; Langel, U. Cell-penetrating peptides: A comparative membrane toxicity study. Anal. Biochem. 2005, 345, 55–65. [CrossRef] [PubMed]
73. Cardozo, A.K.; Buchillier, V.; Mathieu, M.; Chen, J.; Ortis, F.; Ladriere, L.; Allaman-Pillet, N.; Poirot, O.; Kellenberger, S.; Beckmann, J.S.; et al. Cell-permeable peptides induce dose- and length-dependent cytotoxic effects. Biochim. Biophys. Acta 2007, 1768, 2222–2234. [CrossRef] [PubMed]
74. Pfeiffer, D.R.; Gudz, T.I.; Novgorodov, S.A.; Erdahl, W.L. The peptide mastoparan is a potent facilitator of the mitochondrial permeability transition. J. Biol. Chem. 1995, 270, 4923–4932. [CrossRef] [PubMed]
75. Hirai, Y.; Kuwada, M.; Yasuhara, T.; Yoshida, H.; Nakajima, T. A new mast cell degranulating peptide homologous to mastoparan in the venom of japanese hornet (Vespa xanthoptera). Chem. Pharm. Bull 1979, 27, 1945–1946. [CrossRef] [PubMed]
76. Yamada, Y.; Harashima, H. Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases. Adv. Drug Deliv. Rev. 2008, 60, 1439–1462. [CrossRef] [PubMed]
77. Kilk, K.; El-Andaloussi, S.; Jarver, P.; Meikas, A.; Valkna, A.; Bartfai, T.; Kogerman, P.; Metsis, M.; Langel, U. Evaluation of transportan 10 in PEI mediated plasmid delivery assay. J. Control. Release 2005, 103, 511–523. [CrossRef] [PubMed]
78. Sabatier, J.M.; Vives, E.; Mabrouk, K.; Benjouad, A.; Rochat, H.; Duval, A.; Hue, B.; Bahraoui, E. Evidence for neurotoxic activity of TAT from human immunodeficiency virus type 1. J. Virol. 1991, 65, 961–967. [PubMed]
79. Adenot, M.; Merida, P.; Lahana, R. Applications of a blood–brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 2. Cationic peptide vectors for brain delivery. Chemotherapy 2007, 53, 73–76. [CrossRef] [PubMed]
80. Rousselle, C.; Clair, P.; Smirnova, M.; Kolesnikov, Y.; Pasternak, G.W.; Gac-Breton, S.; Rees, A.R.; Scherrmann, J.M.; Temsamani, J. Improved brain uptake and pharmacological activity of dalargin using a peptide-vector-mediated strategy. J. Pharmacol. Exp. Ther. 2003, 306, 371–376. [CrossRef] [PubMed]
81. Poduslo, J.F.; Curran, G.L. Polyamine modification increases the permeability of proteins at the blood-nerve and blood–brain barriers. J. Neurochem. 1996, 66, 1599–1609. [CrossRef] [PubMed]
82. Lu, W.; Wan, J.; Zhang, Q.; She, Z.; Jiang, X. Aclarubicin-loaded cationic albumin-conjugated PEGylated nanoparticle for glioma chemotherapy in rats. Int. J. Cancer 2007, 120, 420–431. [CrossRef] [PubMed]
83. Bartsch, M.; Weeke-Klimp, A.H.; Meijer, D.K.; Scherphof, G.L.; Kamps, J.A. Cell-specific targeting of lipid-based carriers for odn and DNA. J. Liposome Res. 2005, 15, 59–92. [CrossRef] [PubMed]
84. Shir, A.; Ogris, M.; Wagner, E.; Levitzki, A. Egf receptor-targeted synthetic double-stranded rna eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice. PLoS Med. 2006, 3, e6.
85. Marsh, M.; Helenius, A. Virus entry into animal cells. Adv. Virus Res. 1989, 36, 107–151. [PubMed]
86. Horth, M.; Lambrecht, B.; Khim, M.C.; Bex, F.; Thiriart, C.; Ruysschaert, J.M.; Burny, A.; Brasseur, R. Theoretical and functional analysis of the siv fusion peptide. EMBO J. 1991, 10, 2747–2755. [PubMed]
87. Varkouhi, A.K.; Scholte, M.; Storm, G.; Haisma, H.J. Endosomal escape pathways for delivery of biologicals. J. Control. Release 2011, 151, 220–228. [CrossRef] [PubMed]
88. Frank, P.G.; Woodman, S.E.; Park, D.S.; Lisanti, M.P. Caveolin, caveolae, and endothelial cell function. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 729–736. [CrossRef] [PubMed]
89. Batrakova, E.V.; Li, S.; Alakhov, V.Y.; Miller, D.W.; Kabanov, A.V. Optimal structure requirements for pluronic block copolymers in modifying p-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J. Pharmacol. Exp. Ther. 2003, 304, 845–854. [CrossRef] [PubMed]
90. Zorko, M.; Langel, U. Cell-penetrating peptides: Mechanism and kinetics of cargo delivery. Adv. Drug Deliv. Rev. 2005, 57, 529–545. [CrossRef] [PubMed]
91. Oba, M.; Fukushima, S.; Kanayama, N.; Aoyagi, K.; Nishiyama, N.; Koyama, H.; Kataoka, K. Cyclic RGD peptide-conjugated polyplex micelles as a targetable gene delivery system directed to cells possessing αvβ3 and αvβ5 integrins. Bioconjug. Chem. 2007, 18, 1415–1423. [CrossRef] [PubMed]
92. Pardridge, W.M. Drug and gene targeting to the brain with molecular trojan horses. Nat. Rev. Drug Discov. 2002, 1, 131–139. [CrossRef] [PubMed]
93. De Boer, A.G.; Gaillard, P.J. Drug targeting to the brain. Annu. Rev. Pharmacol. Toxicol. 2007, 47, 323–355. [CrossRef] [PubMed]
94. Gabathuler, R. Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases. Neurobiol. Dis. 2010, 37, 48–57. [CrossRef] [PubMed]
95. Johnsen, K.B.; Moos, T. Revisiting nanoparticle technology for blood–brain barrier transport: Unfolding at the endothelial gate improves the fate of transferrin receptor-targeted liposomes. J. Control. Release 2016, 222, 32–46. [CrossRef] [PubMed]
96. Gregori, M.; Orlando, A.; Re, F.; Sesana, S.; Nardo, L.; Salerno, D.; Mantegazza, F.; Salvati, E.; Zito, A.; Malavasi, F.; et al. Novel antitransferrin receptor antibodies improve the blood–brain barrier crossing efficacy of immunoliposomes. J. Pharm. Sci. 2016, 105, 276–283. [CrossRef] [PubMed]
97. Chen, Z.-L.; Huang, M.; Wang, X.-R.; Fu, J.; Han, M.; Shen, Y.-Q.; Xia, Z.; Gao, J.-Q. Transferrin-modified liposome promotes α-mangostin to penetrate the blood–brain barrier. Nanomed. Nanotechnol. Biol. Med. 2016, 12, 421–430. [CrossRef] [PubMed]
98. Moos, T.; Morgan, E.H. Transferrin and transferrin receptor function in brain barrier systems. Cell. Mol. Neurobiol. 2000, 20, 77–95. [CrossRef] [PubMed]
99. Da Cruz, M.T.; Simoes, S.; de Lima M.C. Improving lipoplex-mediated gene transfer into C6 glioma cells and primary neurons. Exp. Neurol. 2004, 187, 65–75. [CrossRef] [PubMed]
100. Lee, H.J.; Engelhardt, B.; Lesley, J.; Bickel, U.; Pardridge, W.M. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood–brain barrier in mouse. J. Pharmacol. Exp. Ther. 2000, 292, 1048–1052. [PubMed]
101. Ulbrich, K.; Hekmatara, T.; Herbert, E.; Kreuter, J. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood–brain barrier (BBB). Eur. J. Pharm. Biopharm. 2009, 71, 251–256. [CrossRef] [PubMed]
102. Van Rooy, I.; Mastrobattista, E.; Storm, G.; Hennink, W.E.; Schiffelers, R.M. Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain. J. Control. Release 2011, 150, 30–36. [CrossRef] [PubMed]
103. Moos, T.; Morgan, E.H. The metabolism of neuronal iron and its pathogenic role in neurological disease: Review. Ann. N. Y. Acad. Sci. 2004, 1012, 14–26. [CrossRef] [PubMed]
104. Morris, C.M.; Candy, J.M.; Kerwin, J.M.; Edwardson, J.A. Transferrin receptors in the normal human hippocampus and in Alzheimer’s disease. Neuropathol. Appl. Neurobiol. 1994, 20, 473–477. [CrossRef] [PubMed]
105. Kalaria, R.N.; Sromek, S.M.; Grahovac, I.; Harik, S.I. Transferrin receptors of rat and human brain and cerebral microvessels and their status in Alzheimer’s disease. Brain Res. 1992, 585, 87–93. [CrossRef]
106. Wu, J.; Hua, Y.; Keep, R.F.; Nakamura, T.; Hoff, J.T.; Xi, G. Iron and iron-handling proteins in the brain after intracerebral hemorrhage. Stroke 2003, 34, 2964–2969. [CrossRef] [PubMed]
107. Moos, T.; Morgan, E.H. Restricted transport of anti-transferrin receptor antibody (OX26) through the blood–brain barrier in the rat. J. Neurochem. 2001, 79, 119–129. [CrossRef] [PubMed]
108. Bickel, U.; Yoshikawa, T.; Pardridge, W.M. Delivery of peptides and proteins through the blood–brain barrier. Adv. Drug Deliv. Rev. 2001, 46, 247–279. [CrossRef]
109. Qian, Z.M.; Li, H.; Sun, H.; Ho, K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 2002, 54, 561–587. [CrossRef] [PubMed]
110. Inoue, T.; Cavanaugh, P.G.; Steck, P.A.; Brunner, N.; Nicolson, G.L. Differences in transferrin response and numbers of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials. J. Cell. Physiol. 1993, 156, 212–217. [CrossRef] [PubMed]
111. Recht, L.; Torres, C.O.; Smith, T.W.; Raso, V.; Griffin, T.W. Transferrin receptor in normal and neoplastic brain tissue: Implications for brain-tumor immunotherapy. J. Neurosurg. 1990, 72, 941–945. [CrossRef] [PubMed]
112. Kreuter, J. Application of nanoparticles for the delivery of drugs to the brain. Int. Congr. Ser. 2005, 1277, 85–94. [CrossRef]
113. Koo, Y.E.; Reddy, G.R.; Bhojani, M.; Schneider, R.; Philbert, M.A.; Rehemtulla, A.; Ross, B.D.; Kopelman, R. Brain cancer diagnosis and therapy with nanoplatforms. Adv. Drug Deliv. Rev. 2006, 58, 1556–1577. [CrossRef] [PubMed]
114. Bhaskar, S.; Tian, F.; Stoeger, T.; Kreyling, W.; de la Fuente, J.M.; Grazú, V.; Borm, P.; Estrada, G.; Ntziachristos, V.; Razansky, D. Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood–brain barrier: Perspectives on tracking and neuroimaging. Part. Fibre Toxicol. 2010, 7, 3. [CrossRef] [PubMed]
115. Garcia-Garcia, E.; Andrieux, K.; Gil, S.; Couvreur, P. Colloidal carriers and blood-brain barrier (BBB) translocation: A way to deliver drugs to the brain? Int. J. Pharm. 2005, 298, 274–292. [CrossRef] [PubMed]
116. Beier, C.P.; Schmid, C.; Gorlia, T.; Kleinletzenberger, C.; Beier, D.; Grauer, O.; Steinbrecher, A.; Hirschmann, B.; Brawanski, A.; Dietmaier, C.; et al. RNOP-09: PEGylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma-A phase II study. BMC Cancer 2009, 9. [CrossRef] [PubMed]
117. Dakwar, G.R.; Hammad, I.A.; Popov, M.; Linder, C.; Grinberg, S.; Heldman, E.; Stepensky, D. Delivery of proteins to the brain by bolaamphiphilic nano-sized vesicles. J. Control. Release 2012, 160, 315–321. [CrossRef] [PubMed]
118. Philosof-Mazor, L.; Dakwar, G.R.; Popov, M.; Kolusheva, S.; Shames, A.; Linder, C.; Greenberg, S.; Heldman, E.; Stepensky, D.; Jelinek, R. Bolaamphiphilic vesicles encapsulating iron oxide nanoparticles: New vehicles for magnetically targeted drug delivery. Int. J. Pharm. 2013, 450, 241–249. [CrossRef] [PubMed]
119. Jalali, N.; Moztarzadeh, F.; Mozafari, M.; Asgari, S.; Motevalian, M.; Alhosseini, S.N. Surface modification of poly(lactide-co-glycolide) nanoparticles by D-α-tocopheryl polyethylene glycol 1000 succinate as potential carrier for the delivery of drugs to the brain. Colloids Surf. A 2011, 392, 335–342. [CrossRef]
120. Seju, U.; Kumar, A.; Sawant, K.K. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: In vitro and in vivo studies. Acta Biomater. 2011, 7, 4169–4176. [CrossRef] [PubMed]
121. Ke, W.; Shao, K.; Huang, R.; Han, L.; Liu, Y.; Li, J.; Kuang, Y.; Ye, L.; Lou, J.; Jiang, C. Gene delivery targeted to the brain using an angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials 2009, 30, 6976–6985. [CrossRef] [PubMed]
122. Shao, K.; Huang, R.; Li, J.; Han, L.; Ye, L.; Lou, J.; Jiang, C. Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain. J. Control. Release 2010, 147, 118–126. [CrossRef] [PubMed]
123. Kim, J.Y.; Choi, W.I.; Kim, Y.H.; Tae, G. Brain-targeted delivery of protein using chitosan- and RVG peptide-conjugated, pluronic-based nano-carrier. Biomaterials 2013, 34, 1170–1178. [CrossRef] [PubMed]
124. Son, S.; Hwang do, W.; Singha, K.; Jeong, J.H.; Park, T.G.; Lee, D.S.; Kim, W.J. RVG peptide tethered bioreducible polyethylenimine for gene delivery to brain. J. Control. Release 2011, 155, 18–25. [CrossRef] [PubMed]
125. Martins, S.; Tho, I.; Reimold, I.; Fricker, G.; Souto, E.; Ferreira, D.; Brandl, M. Brain delivery of camptothecin by means of solid lipid nanoparticles: Formulation design, in vitro and in vivo studies. Int. J. Pharm. 2012, 439, 49–62. [CrossRef] [PubMed]
126. Venishetty, V.K.; Samala, R.; Komuravelli, R.; Kuncha, M.; Sistla, R.; Diwan, P.V. β-hydroxybutyric acid grafted solid lipid nanoparticles: A novel strategy to improve drug delivery to brain. Nanomedicine 2013, 9, 388–397. [CrossRef] [PubMed]
127. Madan, J.; Pandey, R.S.; Jain, V.; Katare, O.P.; Chandra, R.; Katyal, A. Poly(ethylene)-glycol conjugated solid lipid nanoparticles of noscapine improve biological half-life, brain delivery and efficacy in glioblastoma cells. Nanomedicine 2013, 9, 492–503. [CrossRef] [PubMed]
128. Wang, Y.; Su, W.; Li, Q.; Li, C.; Wang, H.; Li, Y.; Cao, Y.; Chang, J.; Zhang, L. Preparation and evaluation of lidocaine hydrochloride-loaded TAT-conjugated polymeric liposomes for transdermal delivery. Int. J. Pharm. 2013, 441, 748–756. [CrossRef] [PubMed]
129. Borchard, G.; Audus, K.L.; Shi, F.; Kreuter, J. Uptake of surfactant-coated poly(methyl methacrylate)-nanoparticles by bovine brain microvessel endothelial cell monolayers. Int. J. Pharm. 1994, 110, 29–35. [CrossRef]
130. Kreuter, J.; Petrov, V.E.; Kharkevich, D.A.; Alyautdin, R.N. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood–brain barrier using surfactant-coated nanoparticles. J. Control. Release 1997, 49, 81–87. [CrossRef]
131. Wilson, B.; Samanta, M.K.; Santhi, K.; Kumar, K.P.; Paramakrishnan, N.; Suresh, B. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer’s disease. Brain Res. 2008, 1200, 159–168. [CrossRef] [PubMed]
132. Pang, Z.; Lu, W.; Gao, H.; Hu, K.; Chen, J.; Zhang, C.; Gao, X.; Jiang, X.; Zhu, C. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX 26. J. Control. Release 2008, 128, 120–127. [CrossRef] [PubMed]
133. Feng, B.; Tomizawa, K.; Michiue, H.; Miyatake, S.; Han, X.J.; Fujimura, A.; Seno, M.; Kirihata, M.; Matsui, H. Delivery of sodium borocaptate to glioma cells using immunoliposome conjugated with anti-EGFR antibodies by ZZ-His. Biomaterials 2009, 30, 1746–1755. [CrossRef] [PubMed]
134. Furrer, E.; Hulmann, V.; Urech, D.M. Intranasal delivery of ESBA105, a TNF-α-inhibitory scFv antibody fragment to the brain. J. Neuroimmunol. 2009, 215, 65–72. [CrossRef] [PubMed]
135. Allen, T.M.; Cullis, P.R. Drug delivery systems: Entering the mainstream. Science 2004, 303, 1818–1822. [CrossRef] [PubMed]
136. Carlmark, A.; Hawker, C.; Hult, A.; Malkoch, M. New methodologies in the construction of dendritic materials. Chem. Soc. Rev. 2009, 38, 352–362. [CrossRef] [PubMed]
137. Szoka, F.; Jacobson, K.; Derzko, Z.; Papahadjopoulos, D. Fluorescence studies on the mechanism of liposome-cell interactions in vitro. Biochim. Biophys. Acta 1980, 600, 1–18. [CrossRef]
138. Müller, R.H.; Mäder, K.; Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery-A review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50, 161–177. [CrossRef]
139. Vauthier, C.; Bouchemal, K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm. Res. 2009, 26, 1025–1058. [CrossRef] [PubMed]
140. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the epr effect in macromolecular therapeutics: A review. J. Control. Release 2000, 65, 271–284. [CrossRef]
141. Vasir, J.K.; Reddy, M.K.; Labhasetwar, V.D. Nanosystems in drug targeting: Opportunities and challenges. Curr. Nanosci. 2005, 1, 47–64. [CrossRef]
142. Shek, P.N.; Lopez, N.G.; Heath, T.D. Immune response mediated by liposome-associated protein antigens. IV. Modulation of antibody formation by vesicle-encapsulated methotrexate. Immunology 1986, 57, 153–157. [PubMed]
143. Harasym, T.O.; Bally, M.B.; Tardi, P. Clearance properties of liposomes involving conjugated proteins for targeting. Adv. Drug Deliv. Rev. 1998, 32, 99–118. [CrossRef]
144. Klibanov, A.L.; Maruyama, K.; Torchilin, V.P.; Huang, L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990, 268, 235–237. [CrossRef]
145. Woodle, M.C. Sterically stabilized liposome therapeutics. Adv. Drug Deliv.Rev. 1995, 16, 249–265. [CrossRef]
146. Tan, P.H.; Manunta, M.; Ardjomand, N.; Xue, S.A.; Larkin, D.F.; Haskard, D.O.; Taylor, K.M.; George, A.J. Antibody targeted gene transfer to endothelium. J. Gene Med. 2003, 5, 311–323. [CrossRef] [PubMed]
147. Schnyder, A.; Huwyler, J. Drug transport to brain with targeted liposomes. NeuroRx 2005, 2, 99–107. [CrossRef] [PubMed]
148. Xiang, Y.; Liang, L.; Wang, X.; Wang, J.; Zhang, X.; Zhang, Q. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes. J. Control. Release 2011, 152, 402–410. [CrossRef] [PubMed]
149. Ying, X.; Wen, H.; Lu, W.L.; Du, J.; Guo, J.; Tian, W.; Men, Y.; Zhang, Y.; Li, R.J.; Yang, T.Y.; et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J. Control. Release 2010, 141, 183–192. [CrossRef] [PubMed]